Early red nucleus atrophy in relapse‐onset multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Early and Degressive Putamen Atrophy in Multiple Sclerosis
Putamen atrophy and its long-term progress during disease course were recently shown in patients with multiple sclerosis (MS). Here we investigated retrospectively the time point of atrophy onset in patients with relapsing-remitting MS (RRMS). 68 patients with RRMS and 26 healthy controls (HC) were admitted to 3T MRI in a cross-sectional study. We quantitatively analyzed the putamen volume of i...
متن کاملRate of brain atrophy in benign vs early multiple sclerosis.
BACKGROUND Benign multiple sclerosis (MS) is defined by minimal or no disability after many years of observation, therefore a less degenerative disease process is suspected to be present in this subset of patients. OBJECTIVE To compare brain atrophy rates in patients with long-standing benign MS vs typical early MS. DESIGN A longitudinal prospective cohort study and a retrospective database...
متن کاملRegional hippocampal atrophy in multiple sclerosis.
Gray matter brain structures, including deep nuclei and the cerebral cortex, are affected significantly and early in the course of multiple sclerosis and these changes may not be directly related to demyelinating white matter lesions. The hippocampus is an archicortical structure that is critical for memory functions and is especially sensitive to multiple insults including inflammation. We use...
متن کاملDentate nucleus T1 hyperintensity in multiple sclerosis.
Gray matter (GM) damage, in terms of focal lesions, “diffuse” tissue injury, and atrophy is a well-known feature of multiple sclerosis (MS). Recently, T1-hyperintensity on unenhanced T1-weighted sequences has been found in the dentate nuclei of patients with MS with severe disability and high T2 lesion load. Such an abnormality has been interpreted as an additional sign of the neurodegenerative...
متن کاملRed flags for multiple system atrophy.
The clinical diagnosis of multiple system atrophy (MSA) is fraught with difficulty and there are no pathognomonic features to discriminate the parkinsonian variant (MSA-P) from Parkinson's disease (PD). Besides the poor response to levodopa, and the additional presence of pyramidal or cerebellar signs (ataxia) or autonomic failure as major diagnostic criteria, certain other clinical features kn...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Human Brain Mapping
سال: 2020
ISSN: 1065-9471,1097-0193
DOI: 10.1002/hbm.25213